Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Agenus Inc.
National Cancer Institute (NCI)
ViroMissile, Inc.
Angiex, Inc.
Hangzhou DAC Biotechnology Co., Ltd.
3B Pharmaceuticals GmbH
Jonsson Comprehensive Cancer Center
NextPoint Therapeutics, Inc.
National Cancer Institute (NCI)
Prelude Therapeutics
Quadriga Biosciences, Inc.
Ludwig Institute for Cancer Research
Ludwig Institute for Cancer Research
MacroGenics
Celgene
OPKO Health, Inc.
CytoMed Therapeutics Pte Ltd
Pfizer
University Health Network, Toronto
Corcept Therapeutics
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Roswell Park Cancer Institute
Altor BioScience
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Memorial Sloan Kettering Cancer Center
Rutgers, The State University of New Jersey
Valerio Therapeutics
ImmunoFrontier, Inc.
Cellectar Biosciences, Inc.
Pfizer
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Emory University
InSightec
National Institutes of Health Clinical Center (CC)
Poniard Pharmaceuticals